[1] GREENLEE R T，HILL-HARMON M B，MURRAY T，et al. Cancer statistics，2001[J] .CA Cancer J Clin，2001，51:15-36. [2] HENSLEY M L. Epithelial ovarian cancer[J] .Curr Treat Options Oncol，2002，3:131-141. [3] COLEMAN R L. Emerging role of topotecan in front-line treatment of carcinoma of the ovary[J] .Oncologist，2002，7(5):46-55. [4] BOOKMAN M A，MALMSTROM H，BOLIS G，et al. Topotecan for the treatment of advanced epithelial ovariancancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel[J] .J Clin Oncol，1998，16(10):3345-3352. [5] KUDELKA A P，TRESUKOSOL D，EDWARDS C L，et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma[J] .J Clin Oncol，1996，14:1552-1557. [6] SWISHER E M，MUTCH D G，RADER J S，et al. Topotecan in platinum- and paclitaxel-resistant ovarian cancer[J] .Gynecol Oncol，1997，66:480-486. [7] GONZA?LEZ-BECA R，ARRANZ J A，BORREGA P，et al. Weekly paclitaxel and carboplatin followed by topotecan (TCTp) as first-line therapy for patients with advanced epithelial ovarian cancer (AOC) suboptimally debulked. Preliminary results[J] .Proc Am Soc Clin Oncol，2001，20:A856-A861. [8] PFISTERER J，LORTHOLARY A，KIMMIG R，et al. Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages Iib IV. Interim results of a gynecologic cancer Intergroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO[J] .Proc Am Soc Clin Oncol，2003，22:A1793-A1801. [9] ALAN N G，LINA A，MARK J M，et al. Phase II study of sequential doublets: topotecan and carboplatin，followed by paclitaxel and carboplatin，in patients with newly diagnosed advanced ovarian cancer[J] .Gynecol Oncol，2004，94：533-539. [10] LIAN L J，LIN Q Z.Gynecological Concology(妇科肿瘤学)[M] . 3rd ed.Beijing：People’s Medical Publishing House，2000：483. [11] DONG Y L，LI R. Cost-effectiveness analysis of 3 chemotherapy regimens for stomach cancer[J] .Chin Pharm J(中国药学杂志)，1999，34(9)：627-628. [12] HUBEL K，HEGENER K，SCHNELL R，et al. Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute non-lymphocytic leukemia[J] .Ann Hematol，1999，78(2)：73-81. [13] LISA L，SILVIA S，FAUSTO R. Antiemetic therapy[J] .Oncology Hematology，2002，43：93-101. [14] HOSKINS P，EISENHAUER E，BEARE S，et al. Randomized phase II study of schedules of topotecan in previously treated patients with ovarian cancer[J] .J Clin Oncel，1998，16:2233-2237. [15] SCHILLER J H，KIM K，HUSTSON P，et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung[J] .J Clin Oncol(临床肿瘤杂志)，1996，14：2345-2352.